Minimal Change Disease

 MINIMAL CHANGE DISEASE 

Minimal change disease (MCD), or nil disease, is the most common cause of nephrotic syndrome in children under age 10. It accounts for about 90 percent of cases in children and about 10–15 percent in adult cases. Patients usually present with heavy proteinuria (>3 g/day), hypoalbuminemia, dyslipidemia, and anasarca. Urine sedi-ment is benign. Diagnosis rests on kidney biopsy. Under light microscopy, the glom-eruli appear normal. There is absence of immune deposits by immunofluorescence. Electron microscopic findings show efface-ment of the epithelial foot processes. Inves-tigators believe that MCD is a T-lymphocyte disease because of its sensitive response to steroids and cyclosporine. It is strongly associated with Hodgkin’s lymphoma, a hematologic malignancy. Proteinuria appears to disappear when the malignancy goes into remission. A glomerular perme-ability factor (GPF) derived from a T-cell hybridoma has been identified to cause fusion of the foot processes and protein-uria, when injected into experimental rats. The T-cell hybridoma was made from T cells harvested from a patient with minimal change disease. It is thought that this GPF has TNF-like activity. In addition, epithe-lial damage causes loss of polyanions like heparin sulfate. This loss of charge selectiv-ity allows macromolecules like albumin to pass through the filtration barrier and leak into the urine.

 

In children with idiopathic nephrotic syndrome, treatment with steroids produces immediate results with about 50 percent of cases going into remission in two weeks, and almost all within eight weeks of treatment. Clinical response in adults tends to be slower, but the majority will achieve remission after twelve to six-teen weeks of treatment. Cytotoxic agents, which include cyclophosphamide, chlo-rambucil, azathioprine, mycophenolate mofetil, and cyclosporine are reserved for relapsers and steroid-resistant cases.

Comments

Post a Comment

Popular posts from this blog

Tissue Damage Pathways: Hypersensitivity Reactions

TISSUE DAMAGE PATHWAYS Although the major function of the com-ponents of the immune system is to neu-tralize or destroy the invading organisms or antigen, these reactions often cause “bystander” tissue damage as well. These are called  hypersensitivity reactions , and Gell and Coombs conveniently divided them into five types. Hypersensitivity Reactions TYPE I: IMMEDIATE These reactions are those that involve antigens that react with IgE bound to tissue mast cells or basophils. Activation of the mast cell results in the release of large amounts of pharmacologically active sub-stances. These reactions are rapid (hence immediate) and if injected into the skin a “wheel and flare” reaction can be seen within five to ten minutes. Most anti-gens stimulating IgE are either inhaled or ingested. A perfect example of the inhaled antigen is ragweed pollen. The IgE pro-duction requires helper T cells and T-cell-derived cytokines. IL-4 and IL-13 stimulate IgE production while IFN- γ  is inh...
Read more

Rheumatic Fever

Image
  RHEUMATIC FEVER Acute rheumatic fever (ARF) is a delayed, nonsuppurative sequela of a pharyngeal infection with the group A streptococcus. A latent period of two to three weeks fol-lows the initial streptococcal pharyngitis. The latent period remains the same for each individual patient in the event of a recurrence. This suggests that the patient has already been exposed to more than one streptococcal infection in the past. The onset of disease is usually characterized by an acute febrile illness, which may mani-fest itself in one of three classical ways: (1) The patient may present with migratory arthritis predominantly involving the large joints of the body. (2) There may also be concomitant clinical and laboratory signs of carditis and valvulitis, or carditis and valvulitis may be the only signs of an acute episode. (3) There may be involvement of the central nervous system, manifesting itself as Sydenham’s chorea. The clinical episodes are self-limiting but damage to the valv...
Read more

Hematopoietic Stem Cell Transplantation

Image
  HEMATOPOIETIC STEM CELL TRANSPLANTATION   HSCT involves the infusion of immature blood-forming cells into the circulation of a patient to reconstitute the recipient’s bone marrow. HSCT is a promising form of therapy for patients with certain forms of genetic diseases, specific cancers, and vari-ous blood disorders (Table 18.1). The trans-planted hematopoietic stem cells (HSCs) may come from the patient (autologous HSCT) or from a different stem cell donor (allogeneic HSCT). The field of  clinical HSCT  began in  the late 1940s,  when experiments in mice showed that shielding of the spleen allowed animals to survive oth-erwise lethal total-body irradiation. It was not until the seminal publication by E. Donnall Thomas in the 1957  New England Journal of Medicine , however,   that even transiently successful hema-topoietic transplants were first reported in humans; and at least another decade passed before allogeneic marrow graft-ing really began ...
Read more